Analysts Are Bullish on Top Healthcare Stocks: Intec Pharma Ltd (NTEC), Iovance Biotherapeutics Inc (IOVA)

By Jason Carr

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Intec Pharma Ltd (NTECResearch Report) and Iovance Biotherapeutics Inc (IOVAResearch Report) with bullish sentiments.

Intec Pharma Ltd (NTEC)

In a report released today, Michael Higgins from Ladenburg maintained a Buy rating on Intec Pharma Ltd, with a price target of $15. The company’s shares opened today at $5.45.

Higgins commented:

“We know the AP-cannabis compounds are so oily they require a reservoir, which is unlike the two immediate-release (IR) and one extended-release (XR) films in AP-CD/LD. So again, the films are specific to the API. Management has described AP’s technology as uniquely suited to low soluble drugs, but we do not know if that describes either of the two major pharma’s proprietary drugs.”

According to TipRanks.com, Higgins is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.5% and a 32.4% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Achieve Life Sciences Inc, and Melinta Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Intec Pharma Ltd with a $15 average price target, a 175.2% upside from current levels. In a report issued on May 9, Oppenheimer also assigned a Buy rating to the stock with a $17 price target.

See today’s analyst top recommended stocks >>

Iovance Biotherapeutics Inc (IOVA)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Iovance Biotherapeutics Inc today and set a price target of $20. The company’s shares opened today at $15.

According to TipRanks.com, Livshits is a 1-star analyst with an average return of -5.3% and a 25.0% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Editas Medicine Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Iovance Biotherapeutics Inc with a $22.75 average price target, implying a 51.7% upside from current levels. In a report issued on May 8, Cowen & Co. also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.